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Abstract 
 
 Remote intracardiac hemodynamic monitoring is a growing area of interest to 
help aid in the management of patients with chronic congestive heart failure.  The 
utility of remote hemodynamic monitoring has not previously been investigated 
with a ventricular assist device population.  We present two cases of patients 
with ventricular assist devices in which we employed remote hemodynamic 
monitoring data to aid in patient management. 
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Introduction 
 
Congestive heart failure is a major public health concern with high economic 
burden on society and health care organizations.  Heart failure is the leading 
cause of hospitalization in patients above 65 years of age and is also associated 
with a higher rate of readmissions1.  Several strategies, both invasive and non-
invasive, have been developed to predict the early signs of decompensation and 
optimize management.  Remote hemodynamic monitor systems have gained 
momentum with enthusiasm intensifying after the results of the CardioMEMS™ 
(St. Jude Medical, Inc., St. Paul, MN) Heart Sensor Allows Monitoring of 
Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients 
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(CHAMPION) study, in which patients randomized to treatment guided by 
pulmonary artery pressure data from the CardioMEMS™ device reduced heart 
failure-related hospitalizations at six months2.  Other devices, including 
implantable left atrial pressure sensors with a subcutaneous antenna coil have 
also been studied3. 
 
Readmission rates after left ventricular device (LVAD) implantation are high4.  
Hospital readmissions in LVAD patients occur at a rate of 1.5-2.5 per patient year 
of support with heart failure representing a leading cause5-7.  Persistent heart 
failure early after LVAD implantation is common, occurring in up to 25% of 
patients8.  The usefulness of remote hemodynamic monitoring in patients with 
LVAD is uncertain.  It can theoretically aid in the management of patients with 
LVADs by optimizing medications and pump parameters, thereby reducing 
hospital readmissions.  We present two cases of patients with LVADs whose 
volume status we were able to manage in an outpatient setting by relying on 
information made available by their respective implanted hemodynamic monitors.   
 
Case 1 
 
A 50-year-old, morbidly obese male with nonischemic, dilated cardiomyopathy 
with a left ventricular ejection fraction (LVEF) < 15% and left ventricular internal 
dimension in diastole of 9.1 cm was referred to our institution for management of 
heart failure.  He had persistent heart failure symptoms and poor quality of life, 
despite optimal medical therapy including cardiac resynchronization therapy.   
 
Evaluation for advanced heart failure therapy was initiated.  Right ventricular size 
and function were grossly normal.  Baseline right-sided intracardiac filling 
pressures were normal and mean pulmonary artery pressure measured 18 
mmHg.  The patient ultimately received a HeartWare® (HeartWare®, 
Framingham, MA) LVAD in late January of 2014 and after a relatively benign 
post-operative course, was discharged in two weeks.  Pump speed was initially 
set at 2300 revolutions per minute (RPM) and changed to 2500 RPMs prior to 
discharge.  Over the next 18 months, he had 15 admissions to our institution and 
8 (53%) readmissions dealt with volume status, 5 for volume overload and 3 for 
dehydration. Three additional changes to pump speed were made during this 
period, ultimately maintained at 2900 RPMs.   
 
Because of his body habitus, volume status was difficult to assess by physical 
exam.  In light of his tenuous volume status and frequent admissions, he was 
referred for implantation of CardioMEMS™ performed in December of 2015.  
Figure 1 displays the changes in the patient’s weights prior to implantation.  
Figures 2-5 display the pulmonary artery pressures, the patient weights, LVAD 
flows, and serum creatinine from December 2015 to March 2016 (after 
CardioMEMS™ implantation).   
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During this 3-month window, the medical regimen was adjusted as was the pump 
speed based on hemodynamic data obtained.  A total of eight occurrences of 
medication changes were noted all of which involved adjustments to diuretic 
dose.  Exactly half the adjustments involved increasing the dose and half 
decreasing the dose.  Pump speed was increased to 3000 RPMs during this 
period.  The patient only had two admissions to our institution during this time, 
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one for a concern of his implantable cardiac defibrillator firing and another for 
evaluation of atypical chest pain.  At present time, five months after 
CardioMEMS implantation, he is doing well and has not had any futher 
readmissions.  
 
 
 
 
Case 2 
 
A 66-year-old male with coronary artery disease status post 3-vessel coronary 
artery bypass grafting and resultant ischemic cardiomyopathy with an LVEF < 
15% was referred to our institution for advanced heart failure options.  He had 
recurrent hospitalizations for decompensated heart failure in the prior year.  In 
April of 2014, his pacemaker was upgraded to a CRT/BiV ICD and a left atrial 
pressure-sensing device was implanted simultaneously as part of the Left Atrial 
Pressure Monitoring to Optimize Heart Failure Therapy (LAPTOP-HF) study.  He 
developed progressively worsening heart failure with New York Heart Association 
Class IV symptoms.  Between September and December of 2015, he was 
admitted for acutely decompensated heart failure 4 times with an average 
hospital length of stay of 5 days.  Given his end-stage ischemic cardiomyopathy, 
a HeartMate II® (Thoractec) was implanted in late December of 2015.   
 
Prior to implantation, the patient had significantly elevated right- and left-sided 
filling pressures with a pulmonary capillary wedge pressure of 35 mmHg as well 
as moderate pulmonary hypertension with a mean pulmonary artery pressure of 
40 mmHg and a pulmonary vascular resistance of 2.8 Wood units despite 
inotrope therapy.  His post-operative course was complicated by respiratory 
insufficiency requiring tracheostomy, healthcare associated pneumonia, 
ventricular tachycardia, acute kidney injury, and blood-loss anemia.  He slowly 
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recovered and was subsequently discharged home with physical therapy.  Left 
atrial pressure readings from his previously implanted device were used to aid in 
outpatient medications adjustments.  Figures 6-7 display the left atrial pressure 
readings and patient weights from January 2016 to March 2016. 
 
 
 
 
 
 
  
During this brief 7-week period, the patient’s diuretic regimen was changed twice.  
The initial change was an increase in the dose of his loop diuretic and the second 
was the addition of a thiazide diuretic.  During this period, device speed was 
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changed and RPMs were increased from 8800 to 9400.  Although the left atrial 
pressure remains elevated, he is feeling well and has not have any 
hospitalizations since the implantation of LVAD. 
 
 
Discussion  
 
Fluid retention remains a significant clinical concern in patients with end-stage 
heart failure even after LVAD implantation.  While an LVAD can provide full 
mechanical support with systemic flows close to normal at rest, adjuvant diuretic 
therapy is often still required.  Decompensated heart failure while on a ventricular 
assist support device is a known clinical entity9.  This is likely related to the fact 
that the LVAD is preload dependent and afterload sensitive10, 11. 
 
Traditional noninvasive remote monitoring of heart failure patients requires 
patients to comply with a stringent fluid restriction, daily weight monitoring, and 
self-assessment of edema.  Many patients lack self-care skills and literacy, which 
makes it difficult for them to carry out these tasks.  Compliance rates for even the 
relatively simple task of weighing one’s self on a daily basis is poor12, 13.   As a 
result, many system practices rely on telemonitoring strategies.  The National 
Institute of Health TELE-HF study randomized 1,653 patients to standard care 
versus telemonitoring using an automated telephone based system to collect 
information.  No significant difference between either group was found in terms of 
all-cause mortality or heart failure-related readmissions14.  The failure of similar 
telemonitoring strategies has been replicated but studies do conflict15-17. 
 
Noninvasive monitoring can be utilized in LVAD patients to monitor 
hemodynamics and guide therapy to address fluid retention and symptoms of 
decompensation.  There is currently no data on the utility of these devices in 
patients with durable circulatory support devices. The pitfalls of relying on patient 
self-assessment or telemonitoring could be extrapolated to an LVAD patient 
population although given the careful candidate selection and the need for close, 
frequent follow-up, one would expect this group to be able to comply more 
readily.  It has been our experience that symptomatic fluid retention may persist 
after LVAD implantation.   Management based on intracardiac monitoring devices 
is very promising in optimizing hemodynamics, improving quality of life, and 
reducing hospitalizations. 
 
The advantage of remote hemodynamic monitoring is the ability to identify 
increases in intracardiac and pulmonary pressures before the development of 
heart failure symptoms, sometimes days to weeks earlier14.  The core question of 
implantable hemodynamic monitoring systems is to determine whether frequent 
assessment of intracardiac filling is better at reducing hospitalizations compared 
to traditional tools.  Adamson contends that understanding the pathophysiology 
of the congestive cascade would aid in maintaining euvolemia, by highlighting 
that increases in filling pressures precede the autonomic adaption to such 
increases, and are subsequently followed by changes in weight and the 
development of symptoms such as dyspnea and edema18.  
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This principle is evidenced in both our cases.  In case 1, the patient went from 8 
volume status related admissions over an 18-month period to zero volume status 
related admissions over a 5-month window.  The second patient with a left atrial 
pressure-sensing device had recently undergone LVAD implantation thus any 
success of avoiding hospitalization for decompensated heart failure is 
confounded.  Despite this, we were still able to make adjustments to his 
medication regimen.  Figures 3 and 6 highlight the weight changes in both of our 
patients during remote monitoring.  Although the immediate impact from 
adjustments to diuretic changes to weight is difficult to assess, we believe the 
general downward trend in weight was related to our ability to make frequent 
adjustments based on the remote intracardiac data available.  Interestingly, the 
scatter of data appreciable in Figure 2 would suggest that weight was not the 
driver between medications adjustments.   
 
There are several other potential advantages of remote hemodynamic monitoring 
specific to the LVAD patient population.  In pump thrombosis, increases in 
pulmonary arterial pressures correlate with a rise in serum lactate 
dehydrogenase (LDH)19.  The potential to suspect the diagnosis of device 
thrombosis remotely, before LDH is checked (which requires a clinic visit), or 
more importantly, before the patient develops significant symptoms would be 
invaluable. 
   
Additionally, as LVADs are preload sensitive, remote intracardiac pressure 
monitoring could allow for more accurate pump speed modifications and help 
optimize the unloading of the left ventricle.  In both our patients, we were able to 
increase pump speed successfully while making changes to diuretic regimens. A 
total of four changes to pump speed were made in the patient from case one 
(including one prior to discharge of the recently placed LVAD) without the use of 
remote hemodynamic monitoring while one change was made after implantation.  
The use of invasive hemodynamics for guidance of the LVAD speed adjustment 
was shown to be superior to a traditional echo-guided ramp test20.  
 
Our second patient had pre-LVAD implantation pulmonary hypertension related 
to intracardiac congestion.  Secondary pulmonary hypertension, if severe 
enough, is a contraindication for cardiac transplantation.  The ability to monitor 
pulmonary artery pressures and adjust medications accordingly would be more 
comfortable for patients and help avoid exposing them to the risks of repeated 
right heart catheterizations.  This approach, in fact, may accelerate the 
normalization of pulmonary vascular resistance, highlighting yet another 
advantage of remote hemodynamic monitoring.  In addition to recording 
pulmonary artery pressures, the CardioMEMS™ system monitors heart rate and 
dysrhythmias that could compromise LVAD function2.  This was not an issue with 
our patient.  Given the multiple, distinct advantages of remote hemodynamic 
monitoring, perhaps the trend of future LVAD models will include the ability to 
measure left ventricular end diastolic pressures remotely.  The idea of a “smart” 
pump which can self-adjust pump speed based on built-in hemodynamic 
pressure sensors has already started to circulate in the literature21. 
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The ability of remote hemodynamic monitoring devices to accurately detect 
elevated intracardiac filling pressures is unknown.  Furthermore, the presence of 
continuous-flow, mechanical support device within the left side of the heart may 
reduce the sensitivity of pulmonary artery diastolic pressures.  Nevertheless, the 
potential advantages of remote hemodynamic monitoring the LVAD patient 
population merits focus for future investigations. 
 
In summary, decompensated heart failure and associated congestion remains 
problematic for LVAD patients.  Where traditional methods for assessing volume 
status have proven unreliable, the utility and success of remote invasive 
hemodynamic monitoring systems are clear and should have similar utility and 
success in an LVAD patient.  In our small cohort, such systems have proven 
beneficial.  Further studies including larger cases series and randomized control 
data are needed to validate this claim. 
 
References 
 
1. Blecker S, Paul M, Taksler G, Ogedegbe G and Katz S. Heart failure-
associated hospitalizations in the United States. Journal of the American College 
of Cardiology. 2013;61:1259-67. 
2. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, 
Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, 
Shavelle D, Jeffries B, Yadav JS and Group CTS. Wireless pulmonary artery 
haemodynamic monitoring in chronic heart failure: a randomised controlled trial. 
Lancet. 2011;377:658-66. 
3. Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, Walton 
A, Adamson P, Kar S, Shah PK, Richards M, Eigler NL, Whiting JS, Haas GJ, 
Heywood JT, Frampton CM, Abraham WT and Hemodynamically Guided Home 
Self-Therapy in Severe Heart Failure Patients Study G. Physician-directed 
patient self-management of left atrial pressure in advanced chronic heart failure. 
Circulation. 2010;121:1086-95. 
4. Hernandez RE, Singh SK, Hoang DT, Ali SW, Elayda MA, Mallidi HR, 
Frazier OH and Meyers DE. Present-Day Hospital Readmissions after Left 
Ventricular Assist Device Implantation: A Large Single-Center Study. Tex Heart 
Inst J. 2015;42:419-29. 
5. Forest SJ, Bello R, Friedmann P, Casazza D, Nucci C, Shin JJ, 
D'Alessandro D, Stevens G and Goldstein DJ. Readmissions after ventricular 
assist device: etiologies, patterns, and days out of hospital. Ann Thorac Surg. 
2013;95:1276-81. 
6. Hasin T, Marmor Y, Kremers W, Topilsky Y, Severson CJ, Schirger JA, 
Boilson BA, Clavell AL, Rodeheffer RJ, Frantz RP, Edwards BS, Pereira NL, 
Stulak JM, Joyce L, Daly R, Park SJ and Kushwaha SS. Readmissions after 
implantation of axial flow left ventricular assist device. Journal of the American 
College of Cardiology. 2013;61:153-63. 
7. Smedira NG, Hoercher KJ, Lima B, Mountis MM, Starling RC, Thuita L, 
Schmuhl DM and Blackstone EH. Unplanned hospital readmissions after 
HeartMate II implantation: frequency, risk factors, and impact on resource use 
and survival. JACC Heart Fail. 2013;1:31-9. 
  
 
 
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.11 Page 10 of 10 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
8. Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, 
Starling RC, Chen L, Boyle AJ, Chillcott S, Adamson RM, Blood MS, Camacho 
MT, Idrissi KA, Petty M, Sobieski M, Wright S, Myers TJ, Farrar DJ and 
HeartMate IICI. Clinical management of continuous-flow left ventricular assist 
devices in advanced heart failure. J Heart Lung Transplant. 2010;29:S1-39. 
9. Aissaoui N, Morshuis M, Diebold B, Guerot E and Gummert J. Heart 
failure while on ventricular assist device support: a true clinical entity? Archives 
of cardiovascular diseases. 2013;106:44-51. 
10. Khalil HA, Cohn WE, Metcalfe RW and Frazier OH. Preload sensitivity of 
the Jarvik 2000 and HeartMate II left ventricular assist devices. ASAIO J. 
2008;54:245-8. 
11. Vandenberghe S, Segers P, Meyns B and Verdonck P. Hydrodynamic 
characterisation of ventricular assist devices. Int J Artif Organs. 2001;24:470-7. 
12. Moser DK, Doering LV and Chung ML. Vulnerabilities of patients 
recovering from an exacerbation of chronic heart failure. American heart journal. 
2005;150:984. 
13. van der Wal MH, Jaarsma T, Moser DK, Veeger NJ, van Gilst WH and 
van Veldhuisen DJ. Compliance in heart failure patients: the importance of 
knowledge and beliefs. European heart journal. 2006;27:434-40. 
14. Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, Phillips 
CO, Hodshon BV, Cooper LS and Krumholz HM. Telemonitoring in patients with 
heart failure. The New England journal of medicine. 2010;363:2301-9. 
15. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M, Boll H, 
Kim SS, Koehler K, Lucke S, Honold M, Heinze P, Schweizer T, Braecklein M, 
Kirwan BA, Gelbrich G, Anker SD and Investigators T-H. Telemedical 
Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled 
intervention trial investigating the impact of telemedicine on mortality in 
ambulatory patients with heart failure: study design. Eur J Heart Fail. 
2010;12:1354-62. 
16. Investigators G. Randomised trial of telephone intervention in chronic 
heart failure: DIAL trial. BMJ. 2005;331:425. 
17. Chaudhry SI, Phillips CO, Stewart SS, Riegel B, Mattera JA, Jerant AF 
and Krumholz HM. Telemonitoring for patients with chronic heart failure: a 
systematic review. J Card Fail. 2007;13:56-62. 
18. Adamson PB. Pathophysiology of the transition from chronic 
compensated and acute decompensated heart failure: new insights from 
continuous monitoring devices. Curr Heart Fail Rep. 2009;6:287-92. 
19. Shah P, Mehta VM, Cowger JA, Aaronson KD and Pagani FD. Diagnosis 
of hemolysis and device thrombosis with lactate dehydrogenase during left 
ventricular assist device support. J Heart Lung Transplant. 2014;33:102-4. 
20. Uriel N, Sayer G, Addetia K, Fedson S, Kim GH, Rodgers D, Kruse E, 
Collins K, Adatya S, Sarswat N, Jorde UP, Juricek C, Ota T, Jeevanandam V, 
Burkhoff D and Lang RM. Hemodynamic Ramp Tests in Patients With Left 
Ventricular Assist Devices. JACC Heart Fail. 2016;4:208-17. 
21. Lampert BC and Emani S. Remote hemodynamic monitoring for 
ambulatory left ventricular assist device patients. J Thorac Dis. 2015;7:2165-71. 
 
 
